alt

20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)

March 3-6, 2013, Atlanta

CROI 2013: Challenges and Opportunities for the Development of Long-acting Antiretrovirals [VIDEO]

Marta Boffito from Chelsea and Westminster Hospital in London presented an overview of some of the challenges and opportunities in the development of long-acting antiretroviral agents for HIV treatment and prevention in a themed discussion at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

alt

Read more:

Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo

Presidio Pharmaceuticals and Boehringer Ingelheim will jointly conduct a Phase 2a trial to evaluate an all-oral combination containing its NS4A inhibitor PPI-668 plus faldaprevir and BI 207127, with or without ribavirin, for people with hard-to-treat genotype 1a hepatitis C virus.

alt

Read more:

CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected

Adding the hepatitis C virus (HCV) protease inhibitors simeprevir or faldaprevir to pegylated interferon plus ribavirin produces higher response rates and the potential for shorter treatment for HIV/HCV coinfected people, according to 2 studies presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.alt

Read more:

CROI 2013: Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Men

Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of therapy and improves the likelihood of a cure for HIV positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

alt

Read more:

CROI 2013: Cancer Incidence After Starting Antiretroviral Therapy [VIDEO]

Rates of AIDS-related cancers start to fall not long after initiation of antiretroviral therapy (ART), but non-AIDS cancers rise with increasing time on therapy, according to study findings presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more: